https://orcid.org/0000-0002-1021-3769
References
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020;71:e1–e36.
- Griffith DE. Treatment of Mycobacterium avium Complex (MAC). Semin Respir Crit Care Med. 2018;39:351–361. doi:10.1055/s-0038-1660472
- Wallace RJ Jr, Brown-Elliott BA, McNulty S, et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146:276–282. doi:10.1378/chest.13-2538
- Koyama K, Ohshima N, Kawashima M, et al. Characteristics of pulmonary Mycobacterium avium complex disease diagnosed later in follow-up after negative mycobacterial study including bronchoscopy. Respir Med. 2015;109:1347–1353. doi:10.1016/j.rmed.2015.08.016
- Charoenratanakul S, Dejsomritrutai W, Chaiprasert A. Diagnostic role of fiberoptic bronchoscopy in suspected smear negative pulmonary tuberculosis. Respir Med. 1995;89:621–623. doi:10.1016/0954-6111(95)90231-7
- Sugimoto N, Kubo S, Uehara H, Kaku M. Development and validation of a combined cell-direct polymerase chain reaction-based nucleic acid lateral flow assay for the rapid detection of bacterial pathogens associated with sepsis. J Japanese Assoc Infect Dis. 2017;91:752–758.
- Imai H, Watanabe Y, Shimada D, et al. Utility of a cell-direct polymerase chain reaction-based nucleic acid lateral flow immunoassay for detection of bacteria in peripheral blood leukocytes of suspected sepsis cases. Infect Drug Resist. 2021;4:5137–5144. doi:10.2147/IDR.S345361
- Shimada J, Hayahsi I, Inamatsu T, et al. Clinical trial of in-situ hybridization method for the rapid diagnosis of sepsis. J Infect Chemother. 1999;5:21–31. doi:10.1007/s101560050004